CGRP mAb Iv denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for cgrp mab iv are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Your IV CGRP Monoclonal Antibody — "Not FDA-Approved"

Intravenous CGRP monoclonal antibodies indicated for migraine prevention carry FDA approval. A "not FDA-approved" denial from Humana for one of these agents typically signals a documentation or coding problem rather than a genuine regulatory issue. Common causes include: the claim was submitted under a code that does not match the FDA-approved indication; the drug was used for an off-label purpose that Humana does not recognize as a covered compendia-supported use; or Humana's internal system has not been updated to reflect a recently approved indication. All of these scenarios are correctable on appeal.

## Why This Denial Is Appealable

The FDA approval status of any drug is publicly verifiable through the FDA's prescribing information database. If the drug was prescribed for its FDA-approved indication and dispensed as labeled, the denial mischaracterizes its regulatory status. For off-label uses, the appeal should demonstrate that the use is supported by recognized drug compendia or major specialty society guidelines — which is a separate legal basis for coverage under many plan types.

## Federal Appeal Framework

• Internal appeal: File under ACA §2719 / ERISA §503 within the deadline on your denial letter. The appeal should specifically challenge the factual basis of the "not FDA-approved" characterization with reference to the public FDA record.
• Request the denial basis in writing: You are entitled to the specific clinical criteria and evidence used to support the denial. Request this at the same time you file your appeal.
• External review: If upheld internally, escalate to an IRO within approximately four months of the final internal denial. IROs are well-positioned to evaluate regulatory-status disputes.
• Expedited review: Available for urgent clinical situations.

## Documentation to Gather

1. FDA prescribing information — the full prescribing label for the specific CGRP mAb, downloaded from DailyMed or the FDA website, showing the approved indication and the date of approval. 2. Diagnosis and indication match — chart notes confirming your documented diagnosis matches the FDA-approved indication as written in the label. 3. Prescriber letter — confirms on-label use, cites the FDA indication language directly, and attests that the prescription was written for that approved indication. 4. Humana's denial rationale — the specific language Humana used; your appeal should rebut each stated basis with the FDA documentation. 5. Compendia reference (if off-label) — if the use is off-label, obtain a reference from a recognized drug compendium (e.g., NCCN Drugs and Biologics Compendium, DrugDex) documenting support for the use.

## Criteria-Mapping Structure

| Humana Denial Basis | Rebuttal Evidence | |---|---| | Alleged lack of FDA approval | [FDA label: drug name, approval date, indication language] | | Indication mismatch (if claimed) | [Chart diagnosis note vs. label indication — exact match] | | Prescriber attestation of on-label use | [Prescriber letter, date, NPI] |